February 20, 2008 - Siemens Healthcare announces an exclusive partnership with Prowess Inc. to develop advanced radiation oncology treatment planning software for integration into Siemens' linear accelerators.

This agreement authorizes Siemens Healthcare to share the basic intellectual property of Prowess' patented Direct Aperture Optimization (DAO) planning software, allowing Siemens to incorporate Prowess’ software into the treatment planning tools for its linear accelerators, which, according to Siemens, will help users to reduce the number of segments, monitor units and treatment times.

The Prowess DAO-based Plan-to-Patient tool for Adaptive Radiation Therapy (ART) has been clinically evaluated and is planned to be available in the spring of 2008. The tool works with Siemens' CTVision System, a SOMATOM CT Sliding Gantry on rails combined with an ARTISTE or ONCOR Linear Accelerator. DAO reportedly enables users to make on-line plan corrections based on actual pre-treatment CT scans taken in the treatment room, while the patient is on the linear accelerator’s treatment table.

Siemens is also working on the development of a single arc radiation treatment called Cone Beam Therapy (CBT). The combination of CBT with DAO-based planning software will help improve tumor control for many disease sites, while sparing as much healthy tissue as possible, according to Siemens.

For more information: www.usa.siemens.com/healthcare


Related Content

News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Radiation Oncology

Jan. 8, 2026 — RefleXion Medical, an external-beam theranostic oncology company, has announced the U.S. Food and Drug ...

Time January 13, 2026
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
News | Prostate Cancer

Nov. 10, 2025 — Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a ...

Time November 11, 2025
arrow
News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | Radiation Oncology

Sept. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT has announced ...

Time September 05, 2025
arrow
Subscribe Now